2-(4-bromophenyl)triphenylene | CAS:1158277-56-5

We serve 2-(4-bromophenyl)triphenylene CAS:1158277-56-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-(4-bromophenyl)triphenylene

Chemical Name:2-(4-bromophenyl)triphenylene
CAS.NO:1158277-56-5
Synonyms:/
Molecular Formula:C24H15Br
Molecular Weight:383.28000
 
Specification:
Appearance:White to slight yellow powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 2-(4-bromophenyl)triphenylene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-bromophenyl)triphenylene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-bromophenyl)triphenylene Use and application,2-(4-bromophenyl)triphenylene technical grade,usp/ep/jp grade.


Related News: We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.6,12-Dibromochrysene manufacturer We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.10-Bromo-1-decanol acetate supplier In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.2-(2-(2,2,2-Trifluoroethoxy)phenoxy)ethyl methanesulfonate vendor In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.But now, the metropolis of 11 million in Hubei province has become the face of a deadly coronavirus outbreak — a stigma the people of Wuhan increasingly find themselves unable to shake off.